Anteris Technologies Global 宣布，其Duravr经导管心脏瓣膜的全球临床试验已获得法国监管机构的批准。这一关键性进展为该公司在美国纳斯达克双重上市后，推动其旗舰产品进入重要市场铺平了道路。法国监管的绿灯意味着试验可以在法国境内开展，标志着Duravr瓣膜在满足欧洲乃至全球严格监管标准方面迈出了坚实一步。该试验旨在评估该创新器械的安全性与有效性，有望为患有心脏瓣膜疾病的患者提供新的微创治疗选择。
Anteris Technologies Global 宣布，其Duravr经导管心脏瓣膜的全球临床试验已获得法国监管机构的批准。这一关键性进展为该公司在美国纳斯达克双重上市后，推动其旗舰产品进入重要市场铺平了道路。法国监管的绿灯意味着试验可以在法国境内开展，标志着Duravr瓣膜在满足欧洲乃至全球严格监管标准方面迈出了坚实一步。该试验旨在评估该创新器械的安全性与有效性，有望为患有心脏瓣膜疾病的患者提供新的微创治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.